MX2017011882A - Compositions and methods for targeting cd99 in haematopoietic and lymphoid malignancies. - Google Patents

Compositions and methods for targeting cd99 in haematopoietic and lymphoid malignancies.

Info

Publication number
MX2017011882A
MX2017011882A MX2017011882A MX2017011882A MX2017011882A MX 2017011882 A MX2017011882 A MX 2017011882A MX 2017011882 A MX2017011882 A MX 2017011882A MX 2017011882 A MX2017011882 A MX 2017011882A MX 2017011882 A MX2017011882 A MX 2017011882A
Authority
MX
Mexico
Prior art keywords
myeloid
antibody
compositions
lymphoid
methods
Prior art date
Application number
MX2017011882A
Other languages
Spanish (es)
Inventor
Y Park Christopher
Shiu- Sah Chung Stephen
Tavakkoli Montreh
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2017011882A publication Critical patent/MX2017011882A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions and methods for the treatment of haematopoietic and lymphoid malignancies including CD99+ acute myelogenous leukemias (AML), myelodysplastic syndromes (MDS) and T-cell neoplasms. Disclosed compositions comprise one or more antibody that (a) binds to the extracellular domain of CD99, (b) ligates myeloid or lymphoid malignant cell-surface expressed CD99, ( c) promotes the capping/clustering/aggregation myeloid or lymphoid malignant cell-surface expressed CD99, and (d) induces apoptosis in and consequent cytotoxicity of antibody-ligated CD99+ myeloid or lymphoid malignant cells. Disclosed methods comprise administering an anti-CD99 antibody, either alone or in combination with one or more additional component such as a mobilizing agent, a transmigration blocking agent, and a chemotherapeutic agent, such as daunorubicin, idarubicin, cytarabine, 5-azacytidine, and decitabine.
MX2017011882A 2015-03-18 2016-03-18 Compositions and methods for targeting cd99 in haematopoietic and lymphoid malignancies. MX2017011882A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562135119P 2015-03-18 2015-03-18
PCT/US2016/023303 WO2016149682A2 (en) 2015-03-18 2016-03-18 Compositions and methods for targeting cd99 in haematopoietic and lymphoid malignancies

Publications (1)

Publication Number Publication Date
MX2017011882A true MX2017011882A (en) 2018-04-20

Family

ID=56919925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011882A MX2017011882A (en) 2015-03-18 2016-03-18 Compositions and methods for targeting cd99 in haematopoietic and lymphoid malignancies.

Country Status (9)

Country Link
EP (1) EP3271399A4 (en)
JP (1) JP2018511311A (en)
KR (1) KR20170136535A (en)
CN (1) CN107614531A (en)
AU (1) AU2016232719A1 (en)
BR (1) BR112017019856A2 (en)
CA (1) CA2980038A1 (en)
MX (1) MX2017011882A (en)
WO (1) WO2016149682A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136419A2 (en) * 2018-01-08 2019-07-11 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods for targeting cd99-expressing cancers
IT201800005991A1 (en) * 2018-06-04 2019-12-04 Antibody complex and derivative uses
WO2019234580A1 (en) * 2018-06-04 2019-12-12 Diatheva S.R.L. Anti-cd99 diabody or igg antibody and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1871517A (en) * 2002-02-19 2006-11-29 免疫公司 Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2006024169A1 (en) * 2004-09-01 2006-03-09 Hemax Genome Inc. Genes of the pseudoautosomal region 1 and their use in the diagnosis, treatment and prevention of autoimmune diseases
US8088382B2 (en) * 2005-07-05 2012-01-03 Cornell Research Foundation, Inc. Methods of inhibiting transendothelial migration of neutrophils and monocytes with anti-CD99L2 antibodies
US20110230372A1 (en) * 2008-11-14 2011-09-22 Stc Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and outcome prediction in pediatric b-precursor acute lymphoblastic leukemia
SI2477648T1 (en) * 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
US20150071987A1 (en) * 2012-02-03 2015-03-12 Emory University Immunostimulatory compositions, particles, and uses related thereto
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2015069935A1 (en) * 2013-11-06 2015-05-14 Memorial Sloan-Kettering Cancer Center Compositions and methods for the treatment of acute myeloid leukemias and myelodysplastic syndromes

Also Published As

Publication number Publication date
WO2016149682A2 (en) 2016-09-22
CN107614531A (en) 2018-01-19
AU2016232719A1 (en) 2017-10-12
JP2018511311A (en) 2018-04-26
KR20170136535A (en) 2017-12-11
WO2016149682A3 (en) 2017-01-26
CA2980038A1 (en) 2016-09-22
BR112017019856A2 (en) 2018-05-29
EP3271399A4 (en) 2019-03-20
EP3271399A2 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
PH12016500933A1 (en) Novel combination treatment for acute myeloid leukemia (aml)
PH12019500369A1 (en) Anti-tim-3 antibodies
PH12016501411B1 (en) Bifunctional cytotoxic agents
NZ722326A (en) Tricyclic compounds as anticancer agents
PH12015502087B1 (en) Newcastle disease viruses and uses thereof
WO2014190163A3 (en) Combination therapy for mds
PE20181292A1 (en) ANTI-DLL3-DRUG ANTIBODY CONJUGATES AND METHODS OF USE
MY177989A (en) Lna oligonucleotide carbohydrate conjugates
PH12019502477A1 (en) Use of anti cd70 antibody argx-10 treat acute myeloid leukemia
MX2016007826A (en) Peptidomimetic compounds and antibody-drug conjugates thereof.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2016007851A (en) Peptidomimetic compounds and antibody-drug conjugates thereof.
UY36075A (en) TUBULISINE DERIVATIVES
MX2020006116A (en) Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules.
MX2017011882A (en) Compositions and methods for targeting cd99 in haematopoietic and lymphoid malignancies.
TW201613641A (en) Anti-CD22 antibody-drug conjugates and methods of using thereof
MX2018007823A (en) Bromodomain and extra-terminal protein inhibitor combination therapy.
MX2016015568A (en) Nucleoside derivatives for the treatment of cancer.
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
WO2016081773A3 (en) Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides
MX2016016419A (en) Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance.
MX2016008304A (en) Uses of oligouronates in cancer treatment.
EP3490548A4 (en) Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
EP3413912A4 (en) Compositions and methods for targeting activin signaling to treat cancer
MX2021002818A (en) Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k).